MedTrace Logo

Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery

NCT05084573 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-10-20

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of continuous interscalene block (CISB) using standard bupivacaine versus a single interscalene injection of liposomal bupivacaine (LB) on pain control following surgical fixation of proximal humerus fractures.

Conditions

  • Shoulder Fractures

Interventions

DRUG

Liposomal bupivacaine

Single bolus injection 10mL 1.33% LB

DRUG

Standard bupivacaine

Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Chi Wing Chan · Queen Mary Hospital, Hong Kong

  • Christian Xinshuo Fang · Queen Mary Hospital, Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-07-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05084573 on ClinicalTrials.gov